STK11 and lung adenocarcinoma: STK11/LKB1 inactivating mutations often cooccur with KRAS-activating mutations, and STK11/LKB1 inactivating mutations are also a driver of primary resistance to immunotherapy in KRAS-mutant lung adenocarcinoma (LUAD) (Qian et al., 2023).